CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 50 enrolled
Drug / intervention
Liposomal Bupivacaine +1 moredrug
Likely dose
Liposomal Bupivacaine 266 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03802864
NCT03802864Phase 4Completed
CompareCT.gov

Post-operative Pain Control of Testicular Sperm Extraction Using Liposomal Bupivacaine

Weill Medical College of Cornell University·interventional·Posted Jan 14, 2019·Updated Dec 17, 2020

In Brief

A Phase 4 clinical trial evaluating Liposomal Bupivacaine and Standard Bupivacaine for Male Infertility. Completed, enrolled 50 participants across 1 site.

Detailed Summary

The study is a drug trial comparing the post-operative pain control provided by liposomal bupivacaine (a local anesthetic) against standard bupivacaine (a different formulation of the local anesthetic) for men undergoing testicular sperm extraction.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMale Infertility
CountriesUnited States
CollaboratorsPacira Pharmaceuticals, Inc

Timeline

Phase 4CompletedFinished
20192020202120222023202420252026
First PostedJan 14, 2019
Enrollment StartFeb 4, 2019
Primary CompletionJan 30, 2020
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 7.5 years ago

Interventions

Liposomal Bupivacainedrug

After surgical sperm retrieval, the wound will be injected with liposomal bupivacaine (266 mg) mixed with standard bupivacaine (bupivacaine hydrochloride 50mg) for post-operative pain relief.

Standard Bupivacainedrug

After surgical sperm retrieval, the wound will be injected only with standard bupivacaine (bupivacaine hydrochloride 100mg) for post-operative pain relief.